BiomX (NYSEMKT:PHGE) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of BiomX (NYSEMKT:PHGE) in a research report sent to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $2.00 price objective on the stock. HC Wainwright also issued estimates for BiomX’s Q2 2024 earnings at ($0.12) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.14) EPS and FY2024 earnings at ($0.52) EPS.

BiomX Stock Up 3.7 %

NYSEMKT:PHGE opened at $0.36 on Tuesday. The firm has a market cap of $19.74 million, a price-to-earnings ratio of -0.67 and a beta of 1.31. The business’s fifty day moving average is $0.36 and its 200 day moving average is $0.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.84 and a quick ratio of 2.84.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BiomX stock. Ikarian Capital LLC bought a new position in shares of BiomX Inc. (NYSEMKT:PHGE) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 10,817,327 shares of the company’s stock, valued at approximately $4,868,000. Ikarian Capital LLC owned 19.59% of BiomX at the end of the most recent quarter. Hedge funds and other institutional investors own 40.57% of the company’s stock.

About BiomX

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).